Intraperitoneal Cisplatin and Carboplatin in the Management of Ovarian Cancer
Ovarian cancer is a malignancy which tends to remain localized to the peritoneal cavity for most of its natural history (1,2).
Pharmacokinetic modeling studies have suggested that following intraperitoneal drug delivery it is possible to expose tumor within the cavity to significantly higher drug concentrations than possible following systemic administration (3).
Cisplatin is the single most active antineoplastic agent in the management of ovarian cancer (4).
Experimental data and retrospective evaluation of clinical trials have suggested that there is a relatively steep dose response curve for cisplatin against ovarian cancer (5,6). In addition, pre-clinical evaluation has demonstrated that resistance to cisplatin is often only “relative” with 2–4 fold increases in drug concentrations being capable of overcoming resistance in in vitro systems (7,8).
Unfortunately, the dose of cisplatin which can be administered systemically is limited by both the nephrotoxic and, most importantly, neurotoxic effects of the agent (9). Phase 1 trials of intraperitoneal cisplatin in ovarian cancer
KeywordsToxicity Platinum Leukemia Nitrite Doxorubicin
Unable to display preview. Download preview PDF.
- 13.M. Markman, S. Cleary, S.B. Howell, and W.E. Lucas, Complications of extensive adhesion formation following intraperitoneal chemotherapy Surg. Gynecol. Obstet. 162:445 (1986).Google Scholar
- 17.M. Markman, S. Howell, W.E. Lucas, C.E. Pfeifle, and M.R. Green, Combination intraperitoneal chemotherapy with cisplatin, cytarabine. and doxorubicin for refractory ovarian carcinoma and other malignancies principally confined to the peritoneal cavity. J. Clin. Oncol.. 2:1321, 1984.PubMedGoogle Scholar
- 21.M. Markman, R. Rothman, T. Hakes, B. Reichman, W. Hoskins, S. Rubin, W. Jones, L. Almadrones, and J.L. Lewis Jr., Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin, J. Clin. Oncol., (in press) (1990).Google Scholar
- 24.M. Markman, T. Hakes, B. Reichman, W. Hoskins, S. Rubin, and J.L. Lewis, Jr, Intraperitoneal versus intravenous cisplatin-based therapy in small-volume residual refractory ovarian cancer: evidence supporting an advantage for local drug delivery. Reg. Cancer Treat. 3:10 (1990).Google Scholar
- 26.M.W. DeGregorio, B.L. Lum, W.M. Holleran, B.J. Wilbur, and B.I. Sikic, Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase 1 study of the Northern California Oncology Group, Cancer Chemother. Pharmacol., 18:235 (1986).Google Scholar
- 29.J.L. Speyer, U. Beller, N. Colombo, J. Sorich, J.C. Wernz, H. Hochster, M. Green, R. Porges, F.M. Muggia, R. Canetta, and E.M. Beckman, Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapy, J. Clin. Oncol., 8:1335 (1990).PubMedGoogle Scholar
- 30.T.C. Shea, J.R. Mason, B. Newton, A.M. Storniolo, R. Taetle, and M.R. Green, High dose carboplatin with recombinant human granulocyte-macrophage colony stimulating factor: a phase 1 study, Proc. Am. Soc. Clin. Oncol., 9:286, (1990).Google Scholar
- 31.G. Los, and J. McVie, Carboplatin an alternative for intraperitoneal cisplatin treatment in cancers restricted to the peritoneal cavity? Proc. Am. Soc. Clin. Oncol.. 9:157 (1990).Google Scholar
- 33.T. Hakes, M. Markman, B. Reichman, W. Hoskins, W. Jones, S. Rubin, L. Almadrones, and J.L. Lewis. High intensity intravenous cyclophosphamide/cisplatin and intraperitoneal cisplatin for advanced ovarian cancer. Proc. Am. Soc. Clin. Oncol.. 8:84, 1989.Google Scholar